Efficient drug delivery to lung epithelial lining fluid by aerosolization of ciprofloxacin incorporated into PEGylated liposomes for treatment of respiratory infections

Drug Development and Industrial Pharmacy

Volumn 37, Issue 4, 2011, Pages 367-372

  Chono, Sumio ^a   Suzuki, Hirokazu ^a   Togami, Kohei ^a   Morimoto, Kazuhiro ^a  

^a HOKKAIDO INSTITUTE OF TECHNOLOGY   (Japan)

Author keywords

Aerosol based pulmonary drug delivery system; ciprofloxacin; lung epithelial lining fluid; PEGylated liposomes; respiratory infections

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N [METHOXY(POLYETHYLENEGLYCOL) 2000]; CIPROFLOXACIN; LIPOSOME; MACROGOL 2000; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; LIPOSOMAL DELIVERY; LUNG FLUID; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARTICLE SIZE; RAT; RESPIRATORY TRACT INFECTION;

AEROSOLS; ANIMALS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; CIPROFLOXACIN; DRUG DELIVERY SYSTEMS; EPITHELIUM; L-LACTATE DEHYDROGENASE; LIPOSOMES; LUNG; MALE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RESPIRATORY TRACT INFECTIONS;

EID: 79953253279     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.513389     Document Type: Article

References (38)

1. Baldwin DR, Honeybourne D, Wise R. (1992). Pulmonary disposition of antimicrobial agents: Methodological considerations. Antimicrob Agents Chemother, 36:1171-75.
2. Wilson R, Dowling RB, Jackson AD. (1996). The biology of bacterial colonization and invasion of the respiratory mucosa. Eur Respir J, 9:1523-30. (Pubitemid 26233800)
3. Densen P, Mandell GL. (1980). Phagocyte strategy vs. microbial tactics. Rev Infect Dis, 2:817-38.
4. Horwitz MA, Silverstein SC. (1980). Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes. J Clin Invest, 65:82-94. (Pubitemid 10214334)
5. Krieg DP, Helmke RJ, German VF, Mangos JA. (1988). Resistance of mucoid Pseudomonas aeruginosa to nonopsonic phagocytosis by alveolar macrophages in vitro. Infect Immun, 56:3173-79.
6. Peterson PK, Verhoef J, Sabath LD, Quie PG. (1997). Effect of protein A on staphylococcal opsonization. Infect Immun, 15:760-64.
7. Stiver HG, Zachidniak K, Speert DP. (1988). Inhibition of polymorphonuclear leukocyte chemotaxis by the mucoid exopolysaccharide of Pseudomonas aeruginosa. Clin Invest Med, 11:247-52.
8. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. (2003). Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med, 167:1472-77. (Pubitemid 37363354)
9. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. (1991). Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta, 1066:29-36.
10. Torchilin VP, Omelyanenko VG, Papisov MI, Bogdanov Jr AA, Trubetskoy VS, Herron JN, et al. (1994). Poly(ethylene glycol) on the liposome surface: On the mechanism of polymer-coated liposome longevity. Biochim Biophys Acta, 1195:11-20. (Pubitemid 24318086)
11. Benne CA, Benaissa-Trouw B, van Strijp JA, Kraaijeveld CA, van Iwaarden JF. (1997). Surfactant protein A, but not surfactant protein D, is an opsonin for influenza A virus phagocytosis: Binding and neutralization. Eur J Immunol, 27:886-90. (Pubitemid 27153657)
12. Holmskov U, Mollenhauer J, Madsen J, Vitved L, Gronlund J, Tornoe I, et al. (1999). Cloning of gp-340, a putative opsonin receptor for lung surfactant protein D. Proc Natl Acad Sci USA, 96:10794-99. (Pubitemid 29442223)
13. Johansson J, Curstedt T, Robertson B. (1994). The proteins of the surfactant system. Eur Respir J, 7:372-91. (Pubitemid 24138005)
14. Schagat TL, Wofford JA, Wright JR. (2001). Surfactant protein A enhances alveolar macrophage phagocytosis of apoptotic neutrophils. J Immunol, 166:2727-33. (Pubitemid 32173514)
15. Chono S, Tanino T, Seki T, Morimoto K. (2007). Pharmacokinetic and pharmacodynamic efficacy of intrapulmonary administration of ciprofloxacin for the treatment of respiratory infections. Drug Metab Pharmacokinet, 22:88-95.
16. Geller DE, Rosenfeld M, Waltz DA, Wilmott RW. (2003). Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest, 123:28-36. (Pubitemid 36126710)
17. Togami K, Chono S, Seki T, Morimoto K. (2010). Aerosol-based efficient delivery of telithromycin, a ketolide antimicrobial agent, to lung epithelial lining fluid and alveolar macrophages. Drug Dev Ind Pharm, 36:861-66.
18. Drlica K. (2003). The mutant selection window and antimicrobial resistance. J Antimicrob Chemother, 52:11-17. (Pubitemid 36850078)
19. Chono S, Tanino T, Seki T, Morimoto K. (2006). Influence of particle size on drug delivery to rat alveolar macrophages following pulmonary administration of ciprofloxacin incorporated into liposomes. J Drug Targ, 14:557-66. (Pubitemid 44592889)
20. Bangham AD, Standish MM, Watkins JC. (1965). Diffusion of univalent ions across the lamellae of swollen phospholipids. JMol Biol, 13:238-52.
21. Funato K, Yoda R, Kiwada H. (1992). Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. Biochim Biophys Acta, 1103:198-204.
22. Derksen JT, Morselt HW, Scherphof GL. (1987). Processing of different liposomal markers after in vitro uptake of immunoglobulin- coated liposomes by rat liver macrophages. Biochim Biophys Acta, 931:33-40. (Pubitemid 18099324)
23. Pool GL, French ME, Edwards RA, Huang L, Lumb RH. (1982). Use of radiolabeled hexadecyl cholesterol ester as a liposome marker. Lipids, 17:445-52.
24. Antonini JM, Reasor MJ. (1991). Accumulation of amiodarone and desethylamiodarone by rat alveolar macrophages in cell culture. Biochem Pharmacol, 42:S151-S56.
25. Rennard SI, Basse Gt, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, et al. (1986). Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol, 60:532-38. (Pubitemid 16019939)
26. Tabata K, Yamaoka K, Kaibara A, Suzuki S, Terakawa M, Hata T. (1999). Moment Analysis Program available on Microsoft Excel. Drug Metab Pharmacokinet, 14:286-93.
27. Branford MM. (1976). A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72:248-54.
28. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. (2002). Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents, 19:355-58. (Pubitemid 34308981)
29. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. (2005). Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: An update. J Antimicrob Chemother, 55:601-07. (Pubitemid 40691835)
30. Blaser J, Stone BB, Groner MC, Zinner SH. (1987). Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother, 31:1054-60. (Pubitemid 17099578)
31. Craig WA. (1995). Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis, 22:89-96.
32. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. (1993). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother, 37:1073-81. (Pubitemid 23141323)
33. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. (1995). The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet, 28:143-60.
34. Moore RD, Lietman PS, Smith CR. (2005). Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis, 155:93-99.
35. Toutain PL, del Castillo JR, Bousquet-Melou A. (2002). The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics. Res Vet Sci, 73:105-14. (Pubitemid 35175230)
36. Decker T, Lohmann-Matthes ML. (1988). A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods, 115:61-69.
37. Neu HC, Fang W, Gu JW, Chin NX. (1992). In vitro activity of OPC-17116. Antimicrob Agents Chemother, 36:1310-5.
38. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al. (1998). Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. J Am Med Assoc, 279:125-29. (Pubitemid 28068302)